BRAF and metastatic neoplasm: Patients with BRAF mutant tumors were associated with increased rates of non-metastatic disease at diagnosis (p < 0.0001, chi-square test), while patients with TWT tumors were associated with poorer performance status (ECOG 1+) (n = 7/20, 35%) compared with other TCGA driver genes (n = 21/144, 14.6%; p = 0.028, Fisher’s exact test) (Figure S1c,d).